# SENTRY (NCT04562389)

> Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04562389
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Karyopharm Therapeutics Inc
- Conditions: Myelofibrosis
- Interventions: Selinexor; Selinexor; Placebo; Ruxolitinib
- Enrollment: 353
- Primary outcome: Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan
- Primary outcome: Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0
- Primary outcome: Phase 1: Maximum Tolerated Dose (MTD)
- Primary outcome: Phase 1: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity

## Commentary we found

- YouTube: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sentry-nct04562389